Veto Maine LD 1117 | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and leaders in the generics and biosimilars industry.
Governor Mills: Veto LD 1117
Generic Prescription Medicines Are the Solution to High Drug Costs
#DoesntAddUp

Veto Maine LD 1117

The Maine legislature recently passed a bill, LD 1117. Instead of targeting high drug costs in the state, LD 1117 misses the mark by zeroing in on generic medicines, which save the state, patients and taxpayers more than one billion dollars each year.

The governor of Maine, Janet Mills, has an opportunity to ensure these savings continue by vetoing LD 1117. Generic medicines are not the problem for Maine; they are the solution to high drug costs. 

Veto Maine LD 1117

Maine should support market-based policies that enhance the competition necessary to meaningfully lower brand name prescription drug prices.

LD 1117 takes the wrong approach and jeopardizes patient access and savings. Patients in Maine should make their voices heard and urge the governor to veto this misguided legislation. 

Generic Drug Savings in Maine

Read AAM Statement

Read Blog from AAM CEO Dan Leonard

Dan Leonard Letter to the Editor

Op-eds and Opposition Letters 

Resources

Please see below for shareable resources, press releases and other content relating to this issue. You can also use the search bar in the header of our website to search for specific keywords across all content on the site.

PDFFeb 19, 2021Evan Chernicky
2020-State-Savings-Maine
Download |
Press Release Jun 18, 2021 Rachel Schwartz
AAM Statement on Governor Mill’s Consideration of LD 1117
Press Release Jun 16, 2021 Rachel Schwartz
AAM Statement on Maine LD 1117

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.